Section Arrow
ORKA.NASDAQ
- Oruka Therapeutics Inc
Quotes are at least 15-min delayed:2026/03/09 18:37 EDT
After Hours
Last
 33.65
+0.12 (+0.36%)
Bid
32.5
Ask
34.38
High 33.65 
Low 33.65 
Volume 12.53K 
Regular Hours (Closed)
Last
 33.53
+0.58 (+1.76%)
Day High 
35.64 
Prev. Close
32.95 
1-M High
36.53 
Volume 
101 
Bid
32.5
Ask
34.38
Day Low
32.815 
Open
33.45 
1-M Low
31 
Market Cap 
1.59B 
Currency 美元 
P/E -- 
%Yield 67.21 
10-SMA 34.06 
20-SMA 33.33 
50-SMA 32.41 
52-W High 36.53 
52-W Low 5.485 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.88/-2.43
Enterprise Value
1.60B
Balance Sheet
Book Value Per Share
26.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ANTXAN2 Therapeutics5.25+2.41+84.86%-- 
After Hours 5.09 -0.16 -3.05%
RLMDRelmada Therapeutics7.17+2.72+61.12%-- 
After Hours 6.77 -0.4 -5.58%
IOVAIovance Biotherapeutics5.41+0.275+5.36%-- 
After Hours 5.42 +0.01 +0.18%
IBRXImmunityBio8.45-0.2-2.31%-- 
After Hours 8.4 -0.05 -0.59%
QNCXQuince Therapeutics0.1065+0.0042+4.11%-- 
After Hours 0.105 -0.0015 -1.41%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.